<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02124278</url>
  </required_header>
  <id_info>
    <org_study_id>PUL-042-001</org_study_id>
    <nct_id>NCT02124278</nct_id>
  </id_info>
  <brief_title>Safety and Tolerability of Single Ascending Doses of PUL-042 Inhalation Solution in Healthy Subjects</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PUL-042 Inhalation Solution in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pulmotect, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pulmotect, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose is to determine if single doses of PUL-042 inhalation solution are safe in&#xD;
      healthy subjects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will assess the safety, tolerability, pharmacokinetics and pharmacodynamics of&#xD;
      single ascending doses of PUL-042 inhalation solutions in healthy subjects.&#xD;
&#xD;
      Subjects will be enter a screening period of up to 14 days to determine eligibility. Subjects&#xD;
      will be admitted to the Phase 1 unit the day prior to dosing and remain in the unit until 24&#xD;
      hours post-dose. Subjects will be seen in the clinic at 3 and 7 days post-dose&#xD;
&#xD;
      A modified 3+3 design will be used to determine the maximum tolerated dose (MTD) based on the&#xD;
      occurrence of dose-limiting toxicities (DLTs) defined by Common Terminology Criteria for&#xD;
      Adverse Events (CTCAE) v4. Additional specific DLTs will be defined as: 1) Hypoxia, defined&#xD;
      as a non-artifactual drop in pulse oximetry to &lt; 90% on room air, 2) A decrease in forced&#xD;
      expiratory volume in one second (FEV1) of 12% or greater compared to the last observation&#xD;
      prior to dosing, 3) Any evidence of bronchospasm or wheezing requiring medical intervention.&#xD;
      Doses will be doubled until the maximum tolerated dose (MTD- defined as the largest dose with&#xD;
      0/6 or 1/6 DLTs) is reached.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose-limiting toxicities (DLTs)</measure>
    <time_frame>Dosing to one week post-dose</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>PUL-042 Inhalation Solution</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fixed dose combination of Pam2CSK4 acetate (Pam2) and ODN M362 (ODN) administered as an inhalation solution. Single dose administration by nebulization. Starting dose will be 2.9 micrograms Pam2: 4.25 micrograms ODN. Up to 7 doubling doses may be tested.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sterile water for injection</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Sterile water for injection administered by nebulization</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PUL-042 Inhalation Solution</intervention_name>
    <arm_group_label>PUL-042 Inhalation Solution</arm_group_label>
    <arm_group_label>Sterile water for injection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males or females of non-childbearing potential&#xD;
&#xD;
          -  Body mass index between 18 and 30 kg/m2&#xD;
&#xD;
          -  Normal spirometry&#xD;
&#xD;
          -  Normal diffusing capacity of lung for carbon monoxide&#xD;
&#xD;
          -  Normal pulse oximetry&#xD;
&#xD;
          -  Males willing to practice contraception or have a female partner using contraception&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Febrile&#xD;
&#xD;
          -  Abnormal chest x-ray&#xD;
&#xD;
          -  History of tobacco products within the last year and total exposure of &gt; 5 pack/years&#xD;
&#xD;
          -  Clinically significant laboratory findings&#xD;
&#xD;
          -  History of chronic pulmonary disease&#xD;
&#xD;
          -  History of atopic reactions&#xD;
&#xD;
          -  Mediastinal lymphadenopathy&#xD;
&#xD;
          -  Oral corticosteroid therapy within 4 weeks prior to randomization&#xD;
&#xD;
          -  Alcohol, caffeine or strenuous exercise within 72 hours prior to dosing&#xD;
&#xD;
          -  Grapefruit within 7 days prior to dosing&#xD;
&#xD;
          -  Administration of concomitant medications within 14 days prior to dosing&#xD;
&#xD;
          -  Exposure to any investigational agent with 30 days&#xD;
&#xD;
          -  Significant concurrent illness&#xD;
&#xD;
          -  Know positive for HIV, hepatitis B or hepatitis C&#xD;
&#xD;
          -  Inability to tolerate a nebulization test with sterile water for injection&#xD;
&#xD;
          -  Positive test for drugs of abuse&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>ICON Development Solutions</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>77027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <study_first_submitted>April 24, 2014</study_first_submitted>
  <study_first_submitted_qc>April 25, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 28, 2014</study_first_posted>
  <last_update_submitted>April 28, 2015</last_update_submitted>
  <last_update_submitted_qc>April 28, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 29, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Single ascending dose</keyword>
  <keyword>Safety and tolerability in healthy subjects</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Aspiration</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pam2CSK4 acetate and ODN M362 combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

